Lutetium Lu 177 Vipivotide Tetraxetan Plus ADT/ARPI Improves Frequency, Depth of PSA Responses in mHSPC – OncLive

The combination of Lutetium Lu 177 vipivotide tetraxetan with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) has demonstrated improvements in the frequency and depth of prostate-specific antigen (PSA) responses in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to reporting from OncLive.

The results indicate that adding this radioligand therapy to the standard combination of ADT and ARPI may enhance the initial biochemical response in patients dealing with hormone-sensitive metastatic disease.

PSA responses are critical metrics in the management of prostate cancer, as the depth and frequency of these responses often serve as indicators of treatment efficacy and can influence the subsequent clinical trajectory of the patient.

From a business and market perspective, the application of Lutetium Lu 177 vipivotide tetraxetan in the mHSPC setting represents a strategic move to shift radioligand therapies upstream in the treatment paradigm. Historically, these therapies have been utilized primarily in later stages of the disease, specifically in metastatic castration-resistant prostate cancer (mCRPC), after other treatment options have been exhausted.

Expanding the use of radioligand therapy into the hormone-sensitive phase significantly increases the addressable patient population. This shift could potentially alter the standard of care for mHSPC, which has long been dominated by the combination of ADT, and ARPI.

Market Implications for Radioligand Therapy

The development of targeted radiopharmaceuticals is a high-growth sector within the oncology market. By targeting the prostate-specific membrane antigen (PSMA), Lutetium Lu 177 vipivotide tetraxetan delivers targeted radiation directly to cancer cells, reducing the impact on healthy surrounding tissue.

The ability to show superior PSA responses in the mHSPC population suggests that the combination therapy may provide a more potent initial strike against the tumor burden. For pharmaceutical developers, establishing efficacy in earlier stages of metastatic disease is a key driver for regulatory approval and market penetration.

The competitive landscape for mHSPC is currently defined by the prevalence of ARPIs. The integration of a radioligand component introduces a different mechanism of action—targeted radiotherapy—which complements the hormonal suppression provided by ADT and ARPI.

If these biochemical responses translate into long-term clinical benefits, such as improved progression-free survival or overall survival, the commercial value of the combination therapy would likely increase significantly due to its potential as a first-line or early-intervention option.

The focus on the depth of PSA response is particularly relevant for clinicians and payers, as a more profound reduction in PSA levels is often associated with a more durable response to therapy, potentially reducing the frequency of subsequent treatment switches.